Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$5.01+12.84%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CPIX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful integration with Apotex's U.S. branded business | branded business. | Intact | Integration delays or failures reported in next 4 quarters | Qualitative: No integration delays reported NDA filing planned, asset transfer amendment filed, and executive transitions to Apotex affiliate noted. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development business, not a proven compounder, and the current long-term thesis is in a watch state. Ifetroban has advanced across several Phase 2 programs, but the company remains loss-making and recent financial performance is weak.
The valuation model describes CPIX as cheap versus peers, while also showing a substantial gap between current expectations and its modeled outlook. That signal has medium confidence, and the overall priced-in tag is justified, with no fragility warning. The evidence does not specify what earnings or clinical outcomes the market assumes.
Near term, financial performance remains weak and the chance of missing the next report is flagged for attention, though this is not a price call. Management completed the Apotex transaction, paid a special dividend, and authorized a share repurchase program; its continuing execution focus is advancing ifetroban. Clinical progress and FDA designations support that effort, but they do not establish eventual success.
Over the multi-year view, the central swing factor is whether ifetroban's Phase 2 programs produce enough progress to support further development. Near term, a guidance cut or continued weakening in jobs data would add pressure, while strong results and guidance from healthcare peers could support sector momentum. A litigation filing was reported on October 26, but the evidence gives no details on its possible effect.
CPIX remains a high-risk, loss-making development story, with completed transaction milestones offset by weak recent performance and uncertain clinical outcomes. The 1-to-3-year view depends mainly on ifetroban progress and management execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Cumberland Pharmaceuticals Inc's published investment case. The stated target is No new major litigation or material losses from existing cases. |
| Intact |
| New significant litigation or large legal losses occur |
0 major litigation events vs 0 target News covers NDA plans and trial results; no evidence of new major litigation or material legal losses. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve double-digit revenue growth in 2026 | Cumberland aims for double-digit revenue growth in 2026. | Broken | YoY revenue growth falls below 5% in FY26 | Revenue growth: -98.46% FY2026-Q2; GAAP. Published target: >=10% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 2026-98.464036 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.55 → $-0.55 · observed estimates
$0.04B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-25 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-26 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-27 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-28 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-29 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-30 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-07-31 | $-0.55 | $38,225,000 | 8 / 9 |
| 2026-08-01 | $-0.55 | $38,225,000 | 8 / 9 |
| 2026-08-02 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-03 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-04 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-05 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-06 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-07 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-08 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-09 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-10 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-11 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-12 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-13 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-14 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-15 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-16 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-17 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-18 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-19 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-20 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-21 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-22 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-23 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-24 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-25 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-26 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-27 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-28 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-29 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-30 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-08-31 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-01 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-02 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-03 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-04 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-05 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-06 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-07 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-08 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-09 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-10 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-11 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-12 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-13 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-14 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-15 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-16 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-17 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-18 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-19 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-20 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-21 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-22 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-23 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-24 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-25 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-26 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-27 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-28 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-29 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-09-30 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-01 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-02 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-03 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-04 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-05 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-06 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-07 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-08 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-09 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-10 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-11 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-12 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-13 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-14 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-15 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-16 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-17 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-18 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-19 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-20 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-21 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-22 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-23 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-24 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-25 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-26 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-27 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-28 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-29 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-30 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-10-31 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-11-01 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-11-02 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-11-03 | $-0.55 | $38,225,000 | 1 / 1 |
| 2026-11-04 | $-0.55 | $38,225,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.